Neoadjuvant Treatment in Localized Pancreatic Cancer of the Elderly: A Systematic Review of the Current Literature
Cancers · 22.02.2025 · 17 (5) · 747
DOI: 10.3390/cancers17050747 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 22.02.2025. Verfasst von Elena Orlandi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology-Hematology, Azienda USL of Piacenza, 29121 Piacenza, Italy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Neoadjuvant therapy (NAT) improves surgical outcomes in pancreatic cancer, but its role in elderly patients remains unclear. Due to comorbidities and lower chemotherapy tolerance, assessing NAT’s benefits and risks in this population is essential. This systematic review assesses the impact of NAT on overall survival (OS), surgical resection rates, and treatment-related toxicities(G3-4) in elderly patients with resectable, borderline, or locally advanced pancreatic cancer.
Methods
A systematic search was conducted in PubMed, MEDLINE, EMBASE, Scopus, and Cochrane databases according to PRISMA guidelines. Studies reporting that NAT outcomes in elderly patients (≥70 years) were included. The Newcastle–Ottawa scale was used to assess study quality. Subgroup analyses compared NAT versus upfront surgery and outcomes in elderly versus younger patients.
Results
Twelve studies (four prospective and eight retrospective) including 11,385 patients met the inclusion criteria. Among 9580 elderly patients, only 24% underwent NAT. NAT significantly improved R0 resection rates compared to upfront surgery (p < 0.001), and elderly patients receiving NAT had a median OS of 26.5 (range 15.7–39.1) months versus 20.3 months (range 11.5–23.8) of upfront surgery and versus 36.2 months (range 23.6–43.0) of NAT in young patients. Elderly patients experienced higher rates of major toxicities (17–57.5%). Personalized regimens, such as gemcitabine/nab-paclitaxel, were better tolerated than FOLFIRINOX.
Conclusions
NAT is associated with improved survival and surgical outcomes in elderly pancreatic cancer patients, despite a higher risk of adverse events. Patient selection based on performance status rather than age alone is essential to optimize treatment benefits. Further prospective trials are needed to refine treatment approaches in this population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oncology-Hematology, Azienda USL of Piacenza, 29121 Piacenza, Italy.
- Department of Pharmacy, Azienda USL of Piacenza, 29121 Piacenza, Italy.
- Department of Medicine and Surgery, University of Parma, 43121 Parma, Italy.
- Department of Health Professions Management, Azienda USL of Piacenza, 29121 Piacenza, Italy.
- General Surgery Unit, Department of Medicine and Surgery, Parma University Hospital, 43126 Parma, Italy.
- Department of General Surgery, Azienda USL of Piacenza, 29121 Piacenza, Italy.
ORCID-Profile: Elena Orlandi, Stefano Vecchia, Massimo Guasconi, Gennaro Perrone, Chiara Citterio, Mario Giuffrida
Zitieren
APA
Orlandi, E., Vecchia, S., Anselmi, E., Toscani, I., Guasconi, M., Perrone, G., Citterio, C., Banchini, F., & Giuffrida, M. (2025). Neoadjuvant Treatment in Localized Pancreatic Cancer of the Elderly: A Systematic Review of the Current Literature. Cancers, 17(5), 747. https://doi.org/10.3390/cancers17050747
Vancouver
Orlandi E, Vecchia S, Anselmi E, Toscani I, Guasconi M, Perrone G, et al. Neoadjuvant Treatment in Localized Pancreatic Cancer of the Elderly: A Systematic Review of the Current Literature. Cancers. 2025;17(5):747. doi:10.3390/cancers17050747
BibTeX
@article{Orlandi2025,
author = {Orlandi, Elena and Vecchia, Stefano and Anselmi, Elisa and Toscani, Ilaria and Guasconi, Massimo and Perrone, Gennaro and Citterio, Chiara and Banchini, Filippo and Giuffrida, Mario},
title = {Neoadjuvant Treatment in Localized Pancreatic Cancer of the Elderly: A Systematic Review of the Current Literature},
journal = {Cancers},
year = {2025},
volume = {17},
number = {5},
pages = {747},
doi = {10.3390/cancers17050747}
}
EUVIMED